BriaCell Therapeutics could access a $1-$5 billion market upon approval despite a sub-$30 million cap. See more on BRIA stock ...

A combined analysis of data over years in patients in Phase 2 trials of supports benefits for those up to age 65 and moderate ...

In the realm of oncology, the concept of 'metabolic rewiring' has expanded beyond aerobic glycolysis to encompass various metabolic strategies that cancer cells employ for survival and progression, ...

The Bcl-2 inhibitor venetoclax is highly effective and is another first- or second-line option even if this agent, like BTK inhibitors, also appears to require continuous dosing, said Stadtmauer, ...

They examined the relationship between LNR and overall survival (OS) and progression-free survival (PFS) alongside other ...

A six-week treatment of chemotherapy before chemoradiotherapy could improve survival rates in people with cervical cancer, ...

October 23 is Fallout Day, commemorating the Great War in 2077. To mark the occasion, Bethesda put on a big celebration ...

Adding durvalumab to chemotherapy significantly improved median progression-free survival (PFS) but not median overall survival (OS), while dual checkpoint blockade boosted both PFS and OS. These ...

A horror game within a game, the retro stylings of Tormenture have you play an Atari 2600-style horror within a kids haunted ...

Tanya Gupta, MD, medical oncologist in the Stanford University Department of Medicine, Division of Medical Oncology, evaluates fam-trastuzumab deruxtecan-nxki (Enhertu; T-DXd) and its role in breast ...

A phase three UK trial found that a new approach to administering chemotherapy to cervical cancer patients improved survival risk. Researcher Dr. Mary McCormack and gynecologic oncologist Dr. Brian ...

The U.S. Food and Drug Administration has approved Vyloy (zolbetuximab-clzb) in combination with fluoropyrimidine- and ...